We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cancer Drug Discovered in Sunflower Seed Protein

By LabMedica International staff writers
Posted on 04 Apr 2011
Australian scientists have demonstrated sunflower proteins and their processing machinery are commandeered to produce rogue protein rings in a discovery that could provide avenues to less expensive, plant-based drug manufacturing. More...


Dr. Joshua Mylne hopes his research has found another use for these plants through the manufacture of cheap therapeutic drugs. Dr. Joshua Mylne and Prof. David Craik, both from the University of Queensland's (UQ) Institute for Molecular Bioscience (Brisbane, Australia), unraveled the manner in which sunflower seeds assemble protein rings, one of which has previously demonstrated potential as a drug for cancer.

The study, published March 21, 2011, in the international journal Nature Chemical Biology, revealed that the machinery used to process and mature otherwise dull seed storage proteins is controlled by a protein ring, SFTI, for its own use. Dr. Mylne and Prof. Craik used the model plant Arabidopsis for their research, demonstrating that the sunflower protein-production system could be moved into another species and therefore SFTI could be manufactured in a range of plants.

Whereas this is of interest to researchers by providing an understanding of how new proteins can evolve and how proteins are matured, it has wider applications for drug production. SFTI can be used in its natural form to block breast cancer enzymes, and in a modified form to block enzymes associated with other types of cancer.

These proteins have not been widely used by drug designers despite their potential to fight cancer because of the expense of producing them using conventional, synthetic manufacturing methods.

"Although SFTI and related proteins show great promise as drug templates, the cost to manufacture them is a significant barrier to widespread use,” Dr. Mylne said. "This issue could be solved through plant manufacturing. Seeds are an attractive system for the production of pharmaceuticals, as they are cheap to grow and their contents are stable at room temperature, and sterile inside their coat. There are also established systems in place for their production, harvest, storage, and transportation, meaning they could be the ultimate low-cost drug delivery system.”

Related Links:

University of Queensland Institute for Molecular Bioscience



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Urine Analyzer
respons® UDS100
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.